Norges Bank Buys Shares of 462,094 Repligen Corporation $RGEN

Norges Bank bought a new stake in Repligen Corporation (NASDAQ:RGEN) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 462,094 shares of the biotechnology company’s stock, valued at approximately $75,719,000. Norges Bank owned 0.82% of Repligen at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Iron Triangle Partners LP bought a new stake in shares of Repligen in the third quarter valued at about $36,091,000. Hudson Bay Capital Management LP bought a new stake in shares of Repligen in the third quarter valued at about $2,807,000. Cinctive Capital Management LP bought a new stake in shares of Repligen in the third quarter valued at about $3,398,000. Massachusetts Financial Services Co. MA bought a new stake in shares of Repligen in the fourth quarter valued at about $199,176,000. Finally, Schroder Investment Management Group lifted its holdings in shares of Repligen by 123.2% in the third quarter. Schroder Investment Management Group now owns 460,609 shares of the biotechnology company’s stock valued at $61,570,000 after purchasing an additional 254,212 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Repligen Stock Performance

RGEN opened at $122.31 on Friday. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $175.77. The firm has a market capitalization of $6.90 billion, a PE ratio of 135.90, a PEG ratio of 2.36 and a beta of 1.09. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. The business’s 50-day simple moving average is $118.67 and its 200 day simple moving average is $138.77.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The business had revenue of $194.26 million for the quarter, compared to analyst estimates of $192.05 million. During the same quarter in the prior year, the company posted $0.39 earnings per share. Repligen’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, sell-side analysts expect that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on RGEN. HC Wainwright boosted their price target on Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a report on Monday, March 23rd. Wolfe Research began coverage on Repligen in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price target on the stock. Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Canaccord Genuity Group cut their price target on Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a report on Monday, April 20th. Finally, HSBC dropped their target price on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Repligen currently has an average rating of “Moderate Buy” and an average price target of $164.64.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.